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JPET #70011 Introduction
Propranolol is a widely used nonselective beta-blocking agent which is highly extracted in the liver (Shand, 1976) and exhibits a non-linear first pass metabolism in the rat (Suzuki et al., 1981) due to saturation of hepatic tissue binding (Anderson et al., 1978; Miyauchi et al., 1993) and Michaelis-Menten metabolic enzyme or sequestration clearance (Keiding and Steiness, 1984; Smallwood et al., 1988) as well as metabolic stereo-selectivity. It has been described as a 'problematic' drug in terms of its first-pass metabolism not being properly described (Lalka et al., 1993) .
As the stereo-selective elimination of propranolol enantiomers remains poorly understood (Marier et al., 1998) and as propranolol is marketed as a racemate consisting of the two enantiomers, we examined the contribution of the stereochemistry of propranolol on its hepatic disposition kinetics by investigating the individual disposition kinetics of both R(+) and S(-)-propranolol and the racemate after bolus injection in the single-pass perfused rat liver. In addition, we measured the microsomal protein binding and metabolism of individual propranolol isomers in an in vitro study. These in vitro data were then used to validate the hepatic disposition kinetic model derived from the in situ impulse-response studies using perfusate concentrations.
This study follows our recently reported structure-hepatic disposition relationships of several cationic drugs in the normal and the diseased rat liver (Hung et al., 2001; Hung et al., 2002 ) and here we also determined pharmacokinetic parameters such as hepatocellular influx, efflux, binding and elimination for these optical isomers. Kinetic parameters were derived from a twophase physiologically based organ pharmacokinetic model (Weiss and Roberts, 1996; This article has not been copyedited and formatted. The final version may differ from this version. 
Material and Methods

Chemicals
Monensin sodium (2-[5-ethyltetrahydro-5-[tetrahydro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl) 
In situ perfusion of the isolated rat liver
Perfusion of the isolated rat liver used in this study was performed as described elsewhere (Cheung et al., 1996) . Briefly, male Wistar rats, weighing 200-250 g were anaesthetised using
an intraperitoneal injection of xylazine/ketamine (10/80 mg kg -1 ). The laparatomised rats were heparinized with 200 units heparin injected into the inferior vena cava. The bile duct and the portal vein were cannulated (PE-10, Clay Adams, Franklin Lakes, NJ) and using an intravenous 16-gauge catheter, respectively. The liver was then perfused with propanesulfonic acid]-buffer containing 2% BSA and 15% washed canine red blood cells (RBC), adjusted to pH 7.40 and oxygenated via a silastic tubing lung, ventilated with an atmosphere of 100% pure oxygen. A peristaltic pump was used as non-circulating perfusion system. The animals were sacrificed by thoracotomy once perfusion was established and the inferior vena cava was cannulated for collection of samples. The animals were placed in a temperature-controlled environment at 37 o C. Assessment of liver viability was by macroscopic appearance, measurement of bile flow, oxygen consumption and portal resistance pressure (Cheung et al., 1996) .
This article has not been copyedited and formatted. The final version may differ from this version. 
JPET #70011
7
Perfusions were adjusted to a flow rate of 15 ml/min and given a 10-min period to stabilise before the injection of the first bolus. Aliquots (50 µL) of perfusion medium containing a particular propranolol optical isomer (0.06-0.11 µmole as determined by HPLC assay),
14 C]DMO (1.5x10 6 dpm), and The collected samples were centrifuged and 75 µL aliquots of the supernatant containing 
Perfusion medium binding
Experiments to determine propranolol optical isomer binding were carried out using 2% BSA MOPS buffer (pH 7.4) containing 15% (v/v) pre-washed canine red blood cells. The unbound fraction of the three propranolol optical isomers was determined using an ultra-filtration of a 1
In vitro binding and metabolism of microsomal protein
To assess the effect of monensin on hepatic drug binding and metabolism an in vitro study with a microsomal protein preparation in the presence and absence of monensin was carried out, 
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9 Michaelis-Menten constant for propranolol (Ishida et al., 1992) was used to confirm linear kinetics. The intrinsic elimination clearance (CL int ) was estimated as the product of the slope and the dose divided by the extrapolated initial concentration.
Analytical procedure
The high performance liquid chromatography (HPLC) method employed in this work has been described and validated previously (Hung et al., 2001) .
Data analysis
A two-phase physiologically based organ pharmacokinetic model was used to analyse propranolol isomer disposition in the perfused liver. This model, which describes intersinusoidal mixing also called vascular dispersion (Roberts et al., 1988) , transfer across a permeability barrier, and the intracellular distribution and elimination kinetics (Weiss and Roberts, 1996; Weiss et al., 1997) , has been previously applied to the disposition of diclofenac (Weiss et al., 2000) . In present work this model (as shown in Fig. 1 (Siebert et al., 2004) .
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10 where the permeation rate constant, k in = f uB PS /V B , is the permeation clearance per extracellular volume V B , PS is the permeability-surface area product. k out is the efflux rate constant. The equilibrium amount ratio K v = k cv /k vc characterises the slowly accessible pool for ion-trapping, K b is defined as a rapidly equilibrating intracellular binding sites (microsomal and non-specific binding). k cv and k vc represent the rate constant for transport from cytosol into acidic vesicles (lysosomes and mitochondria) or from acidic vesicles into cytosol, respectively. The elimination rate constant defined as k e = CL int /V C is the intrinsic elimination clearance normalised per cellular volume V C (Hung et al., 2001) . Data were fitted and calculated using Scientist 
Sensitivity analyses
The predicted extraction ratio and mean transit time defined by two-phase physiologically based pharmacokinetic model (E pred and MTT pred ) are defined by Equations (4) and (5) 
where p is the fraction of the Laplace transform of a sum of 2 inverse Gaussian density functions (G 1 and G 2 ) for vascular references not entering hepatocytes. 
where CV 2 is the normalized variance, R N is the efficiency number which characterizes the elimination of solute by the liver,
In the sensitivity analysis, the effects of altering the parameters defining hepatic disposition on E and MTT of propranolol was examined for RS-propranolol by changing the individual model parameter values derived to define propranolol disposition in the perfused liver.
Statistical analysis
All data are presented as mean ± standard deviation. Statistical analysis was performed using a two-way analysis of variance to assess the presence of significance between the control and treatment groups followed by Tukey's post hoc test (including the Kramer extension) to identify the source of the significance within the group. Statistical significance was taken at the level p<0.05.
This article has not been copyedited and formatted. The final version may differ from this version. for estimation of extracellular and cellular volumes. It is apparent that monensin pre-treatment greatly broadened the peak of the outflow profiles compared to controls. Data points measured and data regression lines predicted by the two-phase organ model appeared adequately fitted ( Fig. 3A-C) . Also shown in Fig. 3 that data points and predicted regression lines for both enantiomers and racemic propranolol increased following monensin administration. Table 1 shows the non-parametric moments parameters for the drugs used in the study. No significant differences between control and monensin-treated groups were observed for hepatic extraction ratio and normalized variance for the propranolol optical isomers. However, there was a significant difference in mean transit time between control and treatment groups (Table   This article . No significant differences for the non-parametric parameters were found to exist between the two propranolol enantiomers and racemic propranolol (Table 1) . 
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The determination of the intracellular pH showed no statistically significant differences before and after monensin treatment (7.34 ± 0.19 and 7.27 ± 0.06, respectively). Table 5 ). In contrast, the mean transit time is significantly affected by K v (p<0.01) and K b (p<0.05, Table 5 ). Both the simulated control and monensin-treated groups had similar predicted hepatic extraction and mean transit time values as those obtained from the nonparametric moments analysis (Table 5 ). An analysis of the outflow perfusion concentration-time profiles in the control and the monensin-treated groups (Fig. 3C ) yielded a significant difference in K v (Table 2 ) and such a difference also leads to a model predicted differences in mean transit time which are consistent with moment estimations (Table 5 ).
Discussion
In this study a physiologically based two-phase organ pharmacokinetic model was used to account for vascular dispersion, hepatic permeability, ion-trapping by subcellular acidic organelles, intracellular binding and intrinsic metabolic clearance of propranolol in the perfused rat liver (Roberts et al., 1988) . Resolution of the relative concentration of each transport process by the model followed the conduct of impulse-response profiles of propranolol in control and monensin-treated livers, the propranolol being administered at a sufficiently low dose to avoid a non-linearity in plasma protein binding (Ludden, 1991) , liver binding (Anderson et al., 1978; Miyauchi et al., 1993) or in hepatic metabolism, recognizing that a range of Michaelis constants need to be incorporated under saturable conditions (Ishida et al., 1992) . The model gave a good fit of the data with and without monensin treatment (Fig. 3) and yielded predicted values of hepatic extraction and mean transit time, consistent with model independent moment estimates ( Table 5 ). The individual propranolol enantiomer perfusate concentration-time profile is similar in shape to that observed for the racemate that we have reported earlier (Siebert et al., 2004) . It is evident that monensin increases the peak propranolol outflow concentration and abolishes the initial subsequent rapid decline in outflow concentrations after dosing (Fig. 3) . As is evident from the binding and transport kinetic data derived in Tables 2 and 3 , monensin's effect can be attributed almost exclusively to its reducing the distribution of propranolol into acidic cell organelles.
A further clarification on the disposition of propranolol isomers in the liver is possible from analysis of outflow profiles and the amount of propranolol isomer remaining in the liver over time. Under hypoxic conditions, the metabolism of propranolol is considerably compromised (Elliott et al., 1993) 
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16 profiles obtained in our laboratory using red blood cell free perfusate yielded a similar shape profiles as found for control livers but with a much slower terminal phase. Hypoxia therefore did not appear to affect either the peak outflow concentration or subsequent rapid decline and therefore contrasts with the data obtained with monensin in this work. Analysis of the tissue concentrations showed that the S-isomer has higher tissue levels than the R-isomer, consistent with the high binding to liver proteins as suggested by the in vitro studies (Table 3 ) and previously reported data (Anderson et al., 1978 ). An analysis of propranolol tissue levels over time revealed that the logarithm of the propranolol tissue concentrations decline in a linear manner over time further confirming that the propranolol concentrations used in this work were below those causing saturation.
Stereo-selectivity in the disposition of propranolol enantiomers in the perfused liver is evident for PS, CL int and K b but not K v . Ion-trapping accounts for 47.4% of the hepatic sequestration for both R(+) and S(-) enantiomers. Propranolol has been shown to be stereo-selective in both its response and in its metabolism, the S(-) enantiomer being about 100 times more effective as a beta blocker than the R(+) enantiomer (Barrett and Cullum, 1968; Marier et al., 1998) .
Enantiomers usually vary in their biological and pharmacological effects, and beta-blockers (such as atenolol or propranolol) with a single chiral centre vary in their stereo-selectivity to bind to the β 1 or β 2 adrenergic receptors. Generally the cardiac activity is attributable to the S(-)-enantiomer which has a much higher binding affinity than its R(+)-counterpart (Barrett and Cullum, 1968; Pearson et al., 1989; Stoschitzky et al., 1993; Marier et al., 1998) . It has also been suggested that the pharmacokinetics of the enantiomers in vivo in rabbits are comparable at lower doses but stereo-selective at higher doses, due to hepatic saturation of S(-)-propranolol clearance and that propranolol enantiomer plasma binding is not stereo-selective or dose dependent (Marier et al., 1998) 
. In the dog, a larger distribution volume of S(-)-propranolol has
This article has not been copyedited and formatted. The final version may differ from this version. been suggested (Bai et al., 1983) and it has been shown that there is a larger uptake of S(-)-propranolol into rat heart tissue when compared to R(+)-propranolol (Kawashima et al., 1976) .
The modelling of perfusate impulse-response data in our study has shown that there is a preferential uptake of the S(-)-propranolol enantiomer by the intracellular binding sites relative to R(+)-propranolol ( Table 2 ). The kinetic parameters PS and K b were found to be increased about 1.4-fold for the S(-) compared to the R(+) enantiomer, reflecting the higher binding affinity of the S(-) enantiomer for liver tissue and the rapidly equilibrating binding sites. A similar finding was evident on analysis of an in vitro hepatic microsomal protein binding of propranolol study (Table 3 ). The fraction unbound of S(-)-propranolol was found to be lower than that of R(+)-propranolol (Table 3) . Table 2 shows that the derived intrinsic elimination clearance of the S(-) enantiomer is almost 1.4-fold that compared to the R(+) isomer. This could be explained by the fact that one of the binding sites in question is microsomal protein and this binding is a prerequisite for elimination (i.e. higher microsomal binding facilitates faster elimination by microsomal metabolism). The in vitro metabolism data also showed that the in vitro CL int and unbound drug fraction values for the R(+)-propranolol were significantly different (smaller CL int and larger unbound drug fraction) compared to those of S(-)-propranolol (Table 3) . Thus, one source of propanolol stereo-selectivity is indeed attributable to the hepatic microsomal binding differences between these two propranolol enantiomers.
Given that only 70% microsomal protein homogenised from liver tissue is metabolically active and the average production from microsomal protein of 1 g liver tissue amounts to about 50 mg This article has not been copyedited and formatted. The final version may differ from this version. liver, Table 2 ). The use of our earlier model, which does not explicitly recognise the ion-trapping of drugs by acidic organelles (Weiss et al., 2000) , with the propranolol optical isomers data resulted in a fit with similar 
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The relative contribution of ion-trapping, microsomal and non-specific binding and distribution of unbound drug to overall sequestration of propranolol in the liver can be estimated from a formula described in detail previously (Siebert et al., 2004) . Ion-trapping, microsomal binding and unbound drug distribution account, respectively, for 47.4%, 47.1% and 5.5% of the sequestration of propranolol in the liver. Thus, ion-trapping equals intracellular binding as a key determinant of propranolol hepatic sequestration.
Sensitivity analyses (Table 5) suggest that propranolol extraction is mainly defined by metabolism, permeability and blood flow, each contributing to a similar extent. In contrast, its mean transit time is mainly defined by ion-trapping, intracellular binding, PS and blood flow (Table 5) . No significant differences between control and monensin-treated groups were observed for hepatic extraction ratio for the propranolol optical isomers (Table 1 ). This finding is consistent with hepatic drug extraction being related to lipophilicity (Hung et al., 2001) .
A major limitation in the present analysis is the need to restrict our modelling to sufficiently low concentrations of propranolol, to avoid saturation of metabolism or binding processes. This restriction was imposed by the inability of the physiologically based pharmacokinetic model used in this work to be applied to non-linear data. Clinically, propranolol is normally given in doses, which saturate both metabolism (von Bahr et al., 1982) and protein binding (Ludden, 1991) . In addition, the binding of propranolol in the liver is also saturable (Anderson et al., 1978; Miyauchi et al., 1993) . Modelling of the non-linearity of the hepatic elimination of propranolol is further complicated by the multiple metabolic pathways for propranolol and that some of the cytochrome P450 isozymes have a low affinity for propranolol whereas others have This article has not been copyedited and formatted. The final version may differ from this version. 
20 a high affinity (Ishida et al., 1992) . Work is now in progress to examine whether the parameters generated in this study can be used with non-linear propranolol data following the modelling of saturable metabolism and binding effects.
In conclusion, our study has shown that, firstly, ion-trapping contributes significantly to the hepatic disposition of propranolol. This contribution is most clearly demonstrated by the app. propranolol (p<0.05) and RS-propranolol (p<0.05) but no difference for the K v value for the three isomers both in the control and treatment groups; no significant difference was found to exist between S(-)-propranolol and RS-propranolol for all kinetic parameters. et al., 1974) , where pHi ≈ 7.27 is the cytosolic pH (Le Couteur et al., 1993) , pHv ≈ 4.4 is the lysosomes pH (Daniel, 2003) , pHv ≈ 6.67 is the mitochondria pH in the fasted state (Soboll et al., 1980). b Given that the fraction of lysosomes (f ly so ) and mitochondria (f mito ) to cytosol is 1% and 20% (Rhoades and Pflanzer, 1996) , the overall unbound drug vesicles/intracellular distribution ratio (v:i) for propranolol can be estimated from the individual organelle volume fraction and concentration ratio above using the 
